Company Overview
EUDA Health Holdings Limited operates as a provider of non-invasive healthcare services, with a primary geographic focus on Singapore, Malaysia, and China. The company's service portfolio includes specialized treatments such as bioenergy capsules, stem cell therapy, and CRISPR gene editing, alongside the provision of supplements and property management services. This business model places EUDA within the Real Estate sector, specifically classified under the Real Estate Services industry, a classification that reflects its operational scope involving property management and service delivery rather than traditional development or investment trusts. The company currently supports a workforce of 117 employees and maintains a total market capitalization of $21.49M, while generating annual revenue of $5.16M. These valuation and revenue figures indicate that EUDA is a small-cap entity with a relatively modest revenue base compared to larger peers in the healthcare or real estate sectors, suggesting a niche operational footprint that relies on high-growth potential in emerging therapeutic areas to justify its current market position.
Financial Health
The company reported a total revenue of $5.16M over the trailing twelve-month period, yet it recorded a net income of $-2,064,341 and an EBITDA of $-1,992,526. The significant gap between the positive revenue figure of $5.16M and the substantial net loss of $-2,064,341 reveals a cost structure where expenses, likely driven by the high costs of specialized treatments and research, heavily outweigh operational income. Consequently, the company generated negative free cash flow of $-3,350,164, which indicates a lack of financial flexibility to fund operations or capital expenditures from internal cash generation without relying on external financing. Margin analysis shows a gross margin of 22.4%, an operating margin of -37.0%, and a profit margin of 5.2%, highlighting a scenario where the company retains value from sales but struggles to cover overhead costs effectively before reaching profitability. Regarding liquidity and leverage, EUDA holds cash of $176,584 against total debt of $2.28M, resulting in a debt-to-equity ratio listed as N/A due to the company's negative equity position. The current ratio stands at 0.23, a metric that signals potential short-term liquidity challenges as current assets are less than current liabilities. Furthermore, the return on equity is N/A and the return on assets is -63.9%, metrics that collectively reveal management's current inability to generate positive returns on the capital invested in the business.
Valuation Assessment
Valuation metrics for EUDA show a trailing P/E ratio of 28.43 and a forward P/E of 7.11. The disparity between the high trailing P/E and the significantly lower forward P/E implies that the market expects a substantial reduction in earnings or a shift in profitability calculations for the upcoming year, despite the current reported losses. The price-to-book ratio is -5.69, a negative figure that indicates the market values the company's equity at a significant discount to its book value, often seen in distressed or turnaround situations. Alternative valuation metrics include a price-to-sales ratio of 4.17 and an EV/EBITDA of -11.65, suggesting that investors are pricing the stock based on revenue multiple rather than earnings, given the negative earnings multiple. Historical price action shows a 52-week high of $86.00 and a 52-week low of $6.54; assuming the current trading price aligns with the forward P/E implications, the stock is positioned significantly below the 52-week high, reflecting the market's skepticism regarding the company's near-term earnings trajectory. The beta of -0.12 indicates that the stock's price volatility moves inversely to the broader market, a characteristic that is unusual for real estate services and suggests specific idiosyncratic factors drive its price fluctuations rather than general market sentiment.
Growth & Income
Revenue growth for the trailing twelve months stands at 60.2%, while earnings growth is listed as N/A due to the company's recent net losses. The absence of positive earnings growth combined with high revenue growth implies that the company is expanding its top line but has not yet achieved profitability, meaning earnings are not growing faster than revenue because they are currently negative. Since the dividend yield is N/A and the payout ratio is 0.0%, EUDA does not distribute dividends to shareholders, instead retaining all earnings to reinvest into its growth initiatives and service expansion. The overall growth and income profile for EUDA Health Holdings Limited is characterized by aggressive top-line expansion in the healthcare sector offset by an inability to generate net income, resulting in a growth-oriented strategy with no current income return for investors.